Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
about
Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 MutationsEzogabine skin discoloration is reversible after discontinuationNew antiepileptic medication linked to blue discoloration of the skin and eyesPemetrexed long-term maintenance treatment leading to multiple finger amputation; cardiovascular complications after energy drink consumption; compartment syndrome due to extravasation of intravenous contrast; blue-gray mucocutaneous discoloration wPerspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.A case report: retigabine induced oral mucosal dyspigmentation of the hard palate.KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.Cutaneous Adverse Effects of Neurologic Medications.Recent advances in epilepsy.Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption.The anticonvulsant retigabine suppresses neuronal KV2-mediated currents.Efficacy of Retigabine on Acute Limbic Seizures in Adult Rats.Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.Levetiracetam-Induced Skin Hyperpigmentation: An Extremely Rare Undesirable Side Effect.Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocketLithium improved behavioral and epileptic symptoms in an adolescent with ring chromosome 20 and bipolar disorder not otherwise specified
P2860
Q28550367-506E0E1B-3A1F-4D54-8EF4-30C3E924A181Q33555698-A71558AB-CD15-4F7B-B4CB-C9BECAE39A21Q35019465-EFFDF1BB-803B-4319-8469-9A22F4C96A72Q35106325-8B3E8CD4-BB0F-465B-9D62-7609903DE407Q35761335-30949896-CBEA-48E3-B637-9F5B96450863Q35802130-99AE6157-280B-4827-902F-062BF26E80D9Q37197859-917FFCC2-C99A-4667-854D-FBA6A0F93086Q37406223-280310FA-7A37-494C-A090-1B011623C0D1Q38617833-0810D18B-C093-4380-A6C0-8BA839767C9EQ38749921-E6F7691E-DCDB-43A0-8099-46F9F991C035Q39000942-57C4711C-DDDD-4386-838D-44EEB3841CECQ40806344-9548BDCF-53A5-4257-BD30-48DE388F5330Q41446747-9E14D6A1-455E-4B7A-A429-690E4AFF0A98Q41942478-FE9F2991-FA72-4964-BE25-D57A17E55F58Q44168300-71B98BCA-9718-40C8-9E03-8775D8F9F7A9Q49216454-8E7100DE-A825-42F3-AD76-55687F06C058Q57921983-4132B572-301F-4E4A-B41D-651AE32D0087Q59130093-C827AA1A-0509-4FA2-B2E4-BAB3D5BFA2DC
P2860
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@en
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@nl
type
label
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@en
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@nl
prefLabel
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@en
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@nl
P2093
P1433
P1476
Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
@en
P2093
Elena Didkovsky
Emmilia Hodak
Hana Feuerman
Ilana Kaplan
Reuven Bergman
Tali Garin Shkolnik
P304
P356
10.1001/JAMADERMATOL.2013.8895
P407
P577
2014-09-01T00:00:00Z